Iovance Biotherapeutics (IOVA) Competitors

Amneal Pharmaceuticals (NASDAQ:AMRX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Which has better earnings & valuation, AMRX or IOVA?

Amneal Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$2.79B	1.07	-$116.89M	$0.01	953.50
Iovance Biotherapeutics	$164.07M	5.94	-$372.18M	-$1.23	-2.19

Do analysts rate AMRX or IOVA?

Amneal Pharmaceuticals presently has a consensus target price of $11.60, indicating a potential upside of 21.66%. Iovance Biotherapeutics has a consensus target price of $11.90, indicating a potential upside of 341.56%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Iovance Biotherapeutics	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36

Do institutionals and insiders hold more shares of AMRX or IOVA?

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is AMRX or IOVA more profitable?

Amneal Pharmaceuticals has a net margin of 0.12% compared to Iovance Biotherapeutics' net margin of -161.44%. Iovance Biotherapeutics' return on equity of -52.87% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	0.12%	-189.49%	6.17%
Iovance Biotherapeutics	-161.44%	-52.87%	-41.31%

Does the media favor AMRX or IOVA?

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 17 mentions for Iovance Biotherapeutics and 11 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.62 beat Iovance Biotherapeutics' score of 0.49 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	5 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, AMRX or IOVA?

Amneal Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.

Summary

Amneal Pharmaceuticals beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.